(Repeats with no changes to additional subscribers) J.P. Morgan Securities initiated coverage of Czech drug maker Zentiva and Hungarian drug producer Richter Gedeon with overweight ratings. The brokerage said Zentiva is a standout buying opportunity as its broad spread of sales into Eastern Europe represented a relatively low risk way of playing growth in the branded generic markets. Richter's exposure is attractive on both geographic and portfolio exposure fronts, the key long-term drivers for branded generics companies, JP Morgan said. The brokerage has price targets of 1,557 crowns on Zentiva and 48,126 forints on Richter. (Reporting by Rakesh Sharma in Bangalore) ((Editing by Hari Govind; Reuters Messaging: rakesh.sharma.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: ZENTIVA/RESEARCH JPMORGAN
[Reuters/Finance.cz]